We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $17.5B
1-Year Est. Return 50.95%
This Fund
S&P 500
This Quarter Est. Return
+10.27%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$22.8B
AUM Growth
-$510M
Cap. Flow
-$2.26B
Cap. Flow %
-9.9%
Top 10 Hldgs %
40.08%
Holding
187
New
21
Increased
43
Reduced
39
Closed
22

Top Buys

Rank Stock Value
1
DIS icon
Walt Disney
DIS
+$207M
2
ANSS
Ansys
ANSS
+$201M
3
WWD icon
Woodward
WWD
+$192M
4
SWN
Southwestern Energy Company
SWN
+$168M
5
SQSP
Squarespace, Inc.
SQSP
+$130M

Top Sells

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$294M
2
NDAQ icon
Nasdaq
NDAQ
+$256M
3
CRM icon
Salesforce
CRM
+$231M
4
AZN icon
AstraZeneca
AZN
+$188M
5
ARMK icon
Aramark
ARMK
+$187M

Sector Composition

Rank Sector Weight
1 Healthcare 31.84%
2 Technology 13.48%
3 Financials 9.84%
4 Communication Services 6.79%
5 Industrials 6.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BRKR icon
101
Bruker
BRKR
$8.14B
$2.21M 0.01%
+32,000
New +$2.07M
ELEV
102
DELISTED
Elevation Oncology
ELEV
$2.12M 0.01%
3,527,482
-70,936
-2% -$105K
SMC
103
Summit Midstream
SMC
$419M
$2.04M 0.01%
58,214
– –
GATE
104
DELISTED
Marblegate Acquisition Corp. Class A Common Stock
GATE
$1.66M 0.01%
150,000
– –
GRND.WS
105
DELISTED
Grindr Inc. Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share
GRND.WS
$1.64M 0.01%
540,000
– –
MDGL icon
106
Madrigal Pharmaceuticals
MDGL
$11.8B
$704K ﹤0.01%
3,319
– –
TVRD
107
Tvardi Therapeutics
TVRD
$23.4M
$479K ﹤0.01%
43,229
– –
ROIV icon
108
Roivant Sciences
ROIV
$26.2B
$427K ﹤0.01%
37,000
-636,000
-95% -$7.24M
HCA icon
109
HCA Healthcare
HCA
$89.5B
$406K ﹤0.01%
1,000
– –
FBRX icon
110
Forte Biosciences
FBRX
$1.57B
$406K ﹤0.01%
72,413
-5
-0% -$51
BPMC
111
DELISTED
Blueprint Medicines
BPMC
$370K ﹤0.01%
4,000
– –
KRYS icon
112
Krystal Biotech
KRYS
$9.66B
$364K ﹤0.01%
2,000
– –
AXSM icon
113
Axsome Therapeutics
AXSM
$10.9B
$359K ﹤0.01%
4,000
– –
UTHR icon
114
United Therapeutics
UTHR
$23.1B
$358K ﹤0.01%
1,000
-142,000
-99% -$48M
IMVT icon
115
Immunovant
IMVT
$8.25B
$342K ﹤0.01%
12,000
– –
GKOS icon
116
Glaukos
GKOS
$10.6B
$339K ﹤0.01%
2,600
– –
ACLX
117
DELISTED
Arcellx
ACLX
$334K ﹤0.01%
4,000
– –
BTSG icon
118
BrightSpring Health Services
BTSG
$12.4B
$323K ﹤0.01%
22,000
– –
SAGE
119
DELISTED
Sage Therapeutics
SAGE
$309K ﹤0.01%
42,800
– –
MMSI icon
120
Merit Medical Systems
MMSI
$5.32B
$296K ﹤0.01%
3,000
– –
EHC icon
121
Encompass Health
EHC
$12.4B
$290K ﹤0.01%
3,000
– –
SBRA icon
122
Sabra Healthcare REIT
SBRA
$5.37B
$261K ﹤0.01%
14,000
– –
GMED icon
123
Globus Medical
GMED
$11.2B
$258K ﹤0.01%
3,600
– –
ICUI icon
124
ICU Medical
ICUI
$4.61B
$255K ﹤0.01%
+1,400
New +$207K
GRFS
125
Grifois
GRFS
$5.4B
$249K ﹤0.01%
28,000
– –
3 4
5
6 7

Similar funds

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Farallon Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Farallon Capital Management held 187 positions worth $22.8B, down 2.2% from $23.3B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Farallon Capital Management withdrew a net $2.26B in Q3 2024, closing 22 positions and reducing 39 holdings. Its most notable exit was AstraZeneca, an estimated $188M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 32% of assets, up from 29% a quarter earlier, followed by Technology and Financials.

Against the trend, Farallon Capital Management opened a new position in Woodward worth $198M.

  • Farallon Capital Management's largest Q3 2024 buy was Woodward: 1,154,000 shares worth $198M.
  • Farallon Capital Management added most to Walt Disney in Q3 2024, an estimated $207M increase.
  • Farallon Capital Management's biggest Q3 2024 reduction was UnitedHealth, cutting an estimated $294M.
  • Farallon Capital Management fully exited AstraZeneca in Q3 2024, selling an estimated $188M.
  • Farallon Capital Management's ten largest holdings make up 40% of its $22.8B portfolio in Q3 2024.
  • Farallon Capital Management opened 21 new positions and closed 22 in Q3 2024.
  • Farallon Capital Management's portfolio value fell 2.2% quarter-over-quarter to $22.8B.

Based on Farallon Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.